Johnson & Johnson (NYSE:JNJ) Advances Medicine and Robotics as Its Revenue Outlook Rises

Aditi Sarkar

10 November 2026 03:00 PM AEDT

Johnson & Johnson (NYSE:JNJ) Advances Medicine and Robotics as Its Revenue Outlook Rises

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Third-quarter reported sales increased 5.9% to USD 25.4 billion, supported by its diversified healthcare portfolio.
The company reported adjusted diluted Earnings of USD 2.59 per share during the third quarter.
OTTAVA received market authorization as the company advanced clinical programs across innovative medicines and MedTech.
Reported sales guidance increased to between USD 101.0 billion and USD 101.4 billion for 2026.

Johnson & Johnson (NYSE:JNJ) is navigating a new phase shaped by its latest operational disclosures and financial results. The recent developments connect measurable performance with Business priorities that remain at different stages of execution. Shares closed at USD 282.11 on November 9, 2026, a +2.13% change for the session; Market Capitalisation was approximately USD 679.13 bn. The operational and financial updates provide a closer view of the issues behind the company’s current direction.

Revenue Growth Meets a More Complex Earnings Picture

Third-quarter 2026 sales were USD 25.399 billion, compared with USD 23.993 billion a year earlier. That represents reported growth of 5.9%, while operational sales increased 6.0%. The company recorded GAAP diluted earnings of USD 0.09 per share, affected by special charges associated with the proposed talc litigation resolution and strategic transactions. Adjusted Earnings Per Share were USD 2.59, compared with USD 2.80 a year earlier. These differing measures make it important to distinguish underlying adjusted performance from the accounting effects appearing in reported earnings.

Robotics and Drug Programs Shape the Portfolio

Within medical technology, the company pointed to cardiovascular products, including electrophysiology and Shockwave, as contributors to growth. The OTTAVA table-integrated soft-tissue robotic system received market authorization, broadening its surgical technology portfolio. In innovative medicines, developments included positive Phase 3 findings in multiple myeloma, approval of IMAAVY for warm autoimmune hemolytic anemia and priority review for RYBREVANT FASPRO in advanced head and neck cancer. These regulatory and clinical developments represent different stages of commercial availability and should not be treated as equivalent completed launches.

Guidance Moves Higher

Johnson & Johnson increased the midpoint of its full-year reported sales outlook to USD 101.2 billion. The published range stood at USD 101.0 billion to USD 101.4 billion. Adjusted diluted earnings guidance rose to USD 11.05 to USD 11.15 per share. These projections incorporate management’s assumptions and do not amount to achieved results. The company continues to direct Investment toward its medicine and medical technology franchises, alongside acquisitions and strategic development agreements.

Next Milestones Remain Tied to Execution

Attention now moves to execution against the revised fiscal-year guidance and progress across its regulatory and clinical programs. Commercial introduction of recently authorized technology, assessment of pending regulatory reviews, and the eventual financial contribution from transactions remain subject to their respective implementation timelines. The company has not presented these planned steps as completed future earnings.

FAQs

Q: What is the latest company development?

A: Third-quarter 2026 sales were USD 25.399 billion, compared with USD 23.993 billion a year earlier.

Q: How does the update affect the company’s priorities?

A: Within medical technology, the company pointed to cardiovascular products, including electrophysiology and Shockwave, as contributors to growth.

Q: What is the stated outlook?

A: Attention now moves to execution against the revised fiscal-year guidance and progress across its regulatory and clinical programs.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.